Immunogenicity and safety of inactivated influenza vaccine in healthy Korean children and adolescent

Soohyun Ri, Mi Jeong Kim, Yun Kyung Kim

Research output: Contribution to journalArticle

Abstract

Purpose: This study aimed to evaluate the immunogenicity and safety of a trivalent inactivated influenza vaccine (TIV) among healthy Korean children and adolescents. Methods: From October to December 2008, 65 healthy patients aged 6 months to 18 years who visited Korea University Ansan Hospital for influenza vaccination were enrolled in this study. We measured the hemagglutinin inhibition antibody titers at baseline and 30 days after vaccinating enrollees with split influenza vaccine and calculated the seroprotection rates, geometric mean titers, and seroconversion rates. Local and systemic adverse events were assessed after vaccination. Results: The seroprotection rates against all three viral strains (A/H1N1, A/H3N2, B) were 87.7%, 89.2%, and 89.2% (≥70%), respectively; seroconversion rates were 44.6%, 73.8%, and 63.1% (≥40%), respectively; and seroconversion factors were 4.5, 8.4, and 10.5 (>2.5), respectively. The TIV immunogenicity was acceptable according to the CPMP (Committee for Proprietary Medicinal Products) criteria. Although 48 patients (73.8%) reported one or more adverse events, no severe adverse events such as anaphylaxis and convulsion were observed. Forty-two patients (64.6%) reported a local skin reaction, including redness (29.2%), pain (43.1%), or swelling (41.5%) of the injected site, and 26 (40.0%) reported a systemic reaction: fatigue (23.1%), myalgia (20.0%), headache (10.8%), arthralgia (10.8%), chills (9.2%), or fever (7.7%). Conclusions: This study shows that the immunogenicity of the TIV vaccine is acceptable. As there were no serious adverse events aside from local reactions and mild systemic reactions, this vaccine can be safely used among healthy Korean children and adolescents.

Original languageEnglish
Pages (from-to)35-44
Number of pages10
JournalPediatric Infection and Vaccine
Volume25
Issue number1
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Inactivated Vaccines
Influenza Vaccines
Safety
Vaccination
Vaccines
Chills
Myalgia
Arthralgia
Hemagglutinins
Anaphylaxis
Korea
Human Influenza
Fatigue
Headache
Seizures
Fever
Pain
Skin
Antibodies
Seroconversion

Keywords

  • Immunogenicity
  • Influenza vaccines
  • Safety
  • Vaccine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases

Cite this

Immunogenicity and safety of inactivated influenza vaccine in healthy Korean children and adolescent. / Ri, Soohyun; Kim, Mi Jeong; Kim, Yun Kyung.

In: Pediatric Infection and Vaccine, Vol. 25, No. 1, 01.01.2018, p. 35-44.

Research output: Contribution to journalArticle

@article{bccb981c329746229f2d8f516343538e,
title = "Immunogenicity and safety of inactivated influenza vaccine in healthy Korean children and adolescent",
abstract = "Purpose: This study aimed to evaluate the immunogenicity and safety of a trivalent inactivated influenza vaccine (TIV) among healthy Korean children and adolescents. Methods: From October to December 2008, 65 healthy patients aged 6 months to 18 years who visited Korea University Ansan Hospital for influenza vaccination were enrolled in this study. We measured the hemagglutinin inhibition antibody titers at baseline and 30 days after vaccinating enrollees with split influenza vaccine and calculated the seroprotection rates, geometric mean titers, and seroconversion rates. Local and systemic adverse events were assessed after vaccination. Results: The seroprotection rates against all three viral strains (A/H1N1, A/H3N2, B) were 87.7{\%}, 89.2{\%}, and 89.2{\%} (≥70{\%}), respectively; seroconversion rates were 44.6{\%}, 73.8{\%}, and 63.1{\%} (≥40{\%}), respectively; and seroconversion factors were 4.5, 8.4, and 10.5 (>2.5), respectively. The TIV immunogenicity was acceptable according to the CPMP (Committee for Proprietary Medicinal Products) criteria. Although 48 patients (73.8{\%}) reported one or more adverse events, no severe adverse events such as anaphylaxis and convulsion were observed. Forty-two patients (64.6{\%}) reported a local skin reaction, including redness (29.2{\%}), pain (43.1{\%}), or swelling (41.5{\%}) of the injected site, and 26 (40.0{\%}) reported a systemic reaction: fatigue (23.1{\%}), myalgia (20.0{\%}), headache (10.8{\%}), arthralgia (10.8{\%}), chills (9.2{\%}), or fever (7.7{\%}). Conclusions: This study shows that the immunogenicity of the TIV vaccine is acceptable. As there were no serious adverse events aside from local reactions and mild systemic reactions, this vaccine can be safely used among healthy Korean children and adolescents.",
keywords = "Immunogenicity, Influenza vaccines, Safety, Vaccine",
author = "Soohyun Ri and Kim, {Mi Jeong} and Kim, {Yun Kyung}",
year = "2018",
month = "1",
day = "1",
doi = "10.14776/piv.2018.25.1.35",
language = "English",
volume = "25",
pages = "35--44",
journal = "Pediatric Infection and Vaccine",
issn = "2384-1079",
publisher = "Korean Society of Pediatric Infectious Diseases",
number = "1",

}

TY - JOUR

T1 - Immunogenicity and safety of inactivated influenza vaccine in healthy Korean children and adolescent

AU - Ri, Soohyun

AU - Kim, Mi Jeong

AU - Kim, Yun Kyung

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: This study aimed to evaluate the immunogenicity and safety of a trivalent inactivated influenza vaccine (TIV) among healthy Korean children and adolescents. Methods: From October to December 2008, 65 healthy patients aged 6 months to 18 years who visited Korea University Ansan Hospital for influenza vaccination were enrolled in this study. We measured the hemagglutinin inhibition antibody titers at baseline and 30 days after vaccinating enrollees with split influenza vaccine and calculated the seroprotection rates, geometric mean titers, and seroconversion rates. Local and systemic adverse events were assessed after vaccination. Results: The seroprotection rates against all three viral strains (A/H1N1, A/H3N2, B) were 87.7%, 89.2%, and 89.2% (≥70%), respectively; seroconversion rates were 44.6%, 73.8%, and 63.1% (≥40%), respectively; and seroconversion factors were 4.5, 8.4, and 10.5 (>2.5), respectively. The TIV immunogenicity was acceptable according to the CPMP (Committee for Proprietary Medicinal Products) criteria. Although 48 patients (73.8%) reported one or more adverse events, no severe adverse events such as anaphylaxis and convulsion were observed. Forty-two patients (64.6%) reported a local skin reaction, including redness (29.2%), pain (43.1%), or swelling (41.5%) of the injected site, and 26 (40.0%) reported a systemic reaction: fatigue (23.1%), myalgia (20.0%), headache (10.8%), arthralgia (10.8%), chills (9.2%), or fever (7.7%). Conclusions: This study shows that the immunogenicity of the TIV vaccine is acceptable. As there were no serious adverse events aside from local reactions and mild systemic reactions, this vaccine can be safely used among healthy Korean children and adolescents.

AB - Purpose: This study aimed to evaluate the immunogenicity and safety of a trivalent inactivated influenza vaccine (TIV) among healthy Korean children and adolescents. Methods: From October to December 2008, 65 healthy patients aged 6 months to 18 years who visited Korea University Ansan Hospital for influenza vaccination were enrolled in this study. We measured the hemagglutinin inhibition antibody titers at baseline and 30 days after vaccinating enrollees with split influenza vaccine and calculated the seroprotection rates, geometric mean titers, and seroconversion rates. Local and systemic adverse events were assessed after vaccination. Results: The seroprotection rates against all three viral strains (A/H1N1, A/H3N2, B) were 87.7%, 89.2%, and 89.2% (≥70%), respectively; seroconversion rates were 44.6%, 73.8%, and 63.1% (≥40%), respectively; and seroconversion factors were 4.5, 8.4, and 10.5 (>2.5), respectively. The TIV immunogenicity was acceptable according to the CPMP (Committee for Proprietary Medicinal Products) criteria. Although 48 patients (73.8%) reported one or more adverse events, no severe adverse events such as anaphylaxis and convulsion were observed. Forty-two patients (64.6%) reported a local skin reaction, including redness (29.2%), pain (43.1%), or swelling (41.5%) of the injected site, and 26 (40.0%) reported a systemic reaction: fatigue (23.1%), myalgia (20.0%), headache (10.8%), arthralgia (10.8%), chills (9.2%), or fever (7.7%). Conclusions: This study shows that the immunogenicity of the TIV vaccine is acceptable. As there were no serious adverse events aside from local reactions and mild systemic reactions, this vaccine can be safely used among healthy Korean children and adolescents.

KW - Immunogenicity

KW - Influenza vaccines

KW - Safety

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85046100576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046100576&partnerID=8YFLogxK

U2 - 10.14776/piv.2018.25.1.35

DO - 10.14776/piv.2018.25.1.35

M3 - Article

VL - 25

SP - 35

EP - 44

JO - Pediatric Infection and Vaccine

JF - Pediatric Infection and Vaccine

SN - 2384-1079

IS - 1

ER -